Dry and Wet Age-Related Macular Degeneration – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
The treatment of wet AMD in the United States has been mainly dominated by three anti-VEGF therapies: Roche / Genentech’s off-label Avastin, Roche / Genentech’s Lucentis, and Regeneron’s Eylea. The market is becoming increasingly fragmented; newer entrants Roche’s Vabysmo and Regeneron’s Eylea HD are being increasingly incorporated into the treatment algorithm of wet AMD patients, while competition from biosimilars grows. Using national, longitudinal, patient-level U.S. claims data, this report examines recent trends in the management of wet AMD both among newly diagnosed patients and among patients filling a prescription for a key therapy.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed wet AMD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed wet AMD patients?
- How have Vabysmo and Eylea HD been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of wet AMD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of wet AMD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: Roche / Genentech, Regeneron, Novartis, Biogen, Samsung Bioepis
Key drugs: Avastin, Eylea, Lucentis, Beovu, Mvasi, Zirabev, Vabysmo, Susvimo, Byooviz, Cimerli
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Table of contents
Kanika Kaushik, Pharm.D., Associate Healthcare Research & Data Analyst, CNS and Ophthalmology. In her current role at Clarivate, Ms. Kaushik works on pipeline analysis, drug profiling, pricing analysis, and KOL research. Prior to joining the company, she was a clinical pharmacologist working on research projects in the areas of psychiatry, nephrology, and medical devices. She holds a master’s degree in pharmacy from Rajiv Gandhi University of Health Sciences in Bangalore.